Azitra, Inc. (AZTR)

Market Cap	3.03M
Revenue (ttm)	n/a
Net Income (ttm)	-9.36M
Shares Out	3.52M
EPS (ttm)	-5.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,968
Open	0.8758
Previous Close	0.8809
Day's Range	0.8500 - 0.9100
52-Week Range	0.7015 - 4.4470
Beta	-1.60
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2025

About AZTR

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epider...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2023
• Employees: 12
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: AZTR
• Website: https://azitrainc.com

Financial Performance

In 2024, Azitra's revenue was $7,500, a decrease of -98.91% compared to the previous year's $686,000. Losses were -$8.97 million, -29.05% less than in 2023.